化学名称: N-((2S,3R,4S,6R)-2-(((3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-Ethyl-12,13-dihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-7-methoxy-3,5,7,9,11,13-hexamethyl-2,10-dioxooxacyclotetradecan-6-yl)oxy)-3-hydroxy-6-methyltetrahydro-2H-pyran-4-yl)-N-methylnitrous amide
微笑: O=C([C@H](C)[C@@H](O[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)[C@H](C)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)N=O)C[C@@H](C)O2)[C@](C)(OC)C[C@H]3C)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C3=O
印地语: InChI=1S/C7H10O4/c1-2-11-6(10)7(3-4-7)5(8)9/h2-4H2,1H3,(H,8,9)
Stability indicating HPLC-ECD method for the analysis of clarithromycin in pharmaceutical dosage forms: method scaling versus re-validation
By Makoni, Pedzisai A.; Chikukwa, Mellisa T. R.; Khamanga, Sandile M. M.; Walker, Roderick B.
From Scientia Pharmaceutica (2019), 87(4), 31
Stability indicating Rp-Hplc method development and validation for the simultaneous estimation of gemcitabine and clarithromycin in bulk and pharmaceutical dosage form
By Kumar, Y. Anil; Sirisha, Y.; Harini, A. L.; Prathyusha, A.
From World Journal of Pharmaceutical Research (2018), 7(8Spec.Iss.), 1-8
Selecting optimal columns for clarithromycin impurity analysis according to the quantitative relationship of hydrophobic subtraction model
By Zhang Xia; Hu Changqin
From Journal of pharmaceutical and biomedical analysis (2017), 136, 162-169